Download PDF
Thromb Haemost 2006; 95(03): 587-588
DOI: 10.1160/TH05-07-0490
Letters to the Editor
Schattauer GmbH

lnterleukin-6 is a determinant of PAI-1 levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene

Anna Rita Bonfigli
1   Diabetology Unit, INRCA, Ancona
,
Maurizio Marra
1   Diabetology Unit, INRCA, Ancona
,
Cristina Sirolla
1   Diabetology Unit, INRCA, Ancona
,
Massimo Boemi
1   Diabetology Unit, INRCA, Ancona
,
Daniela Mari
2   IRCCS Maggiore Hospital, Department of Internal Medicine, Milan
,
Elisabetta Sacchi
3   L. Sacco Hospital, Department of Immunology and Transfusion, Milan
,
Antonio Procopio
4   Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona
5   Centre of Otology, INRCA, Ancona
,
Rina Recchioni
5   Centre of Otology, INRCA, Ancona
,
Claudio Franceschi
6   Centre of Molecular Biology and Genetics, INRCA, Ancona
7   Department of Experimental Pathology, University of Bologna; Italy
,
Simona Giovagnetti
6   Centre of Molecular Biology and Genetics, INRCA, Ancona
,
Roberto Testa
1   Diabetology Unit, INRCA, Ancona
› Author AffiliationsFinancial support: This work was supported in part by a grant from the Italian Health Ministry fund “Pro-getto Finalizzato FIRB code RBNE018AAP_007: Identificazione di profili genomici nu-cleo-mitocondriali nella patogenesi di malattie comuni età-associate. Implicationi diagnostiche terapeutiche”, and Emilia Romagna Project “ER-GenTech”, FP6 EU Project “T-CIA”.
Further Information

Publication History

Received 12 July 2005

Accepted after resubmission 22 February 2005

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Juhan-vague I, Alessi MC, Mavri A. et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 01: 1575-9.
    CrossrefPubMedGoogle Scholar
  • 2 Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
    CrossrefPubMedGoogle Scholar
  • 3 Dong J, Fujii S, Li H. et al. Interleukin-6 and mev-astatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta. Arte-rioscler Thromb Vase Biol 2005; 25: 1078-84.
    CrossrefPubMedGoogle Scholar
  • 4 Rega G, Kaun C, Weiss TW. et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005; 111: 1938-15.
    CrossrefPubMedGoogle Scholar
  • 5 Dawson SJ, Wiman B, Hamsten A. et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-15.
    PubMedGoogle Scholar
  • 6 Plomgaard P, Keller P, Keller C. et al. TNF-a but not IL-6, stimulates plasminogen activator inhibitor 1 (PAI-1) expression inhuman subcutaneous adipose tissue. J Appl Physiol 2005; 98: 2019-23.
    CrossrefPubMedGoogle Scholar
  • 7 Bastelica D, Mavri A, Verdierl M. et al. Relationships between fibrinolytic and inflammatory parameters inhuman adipose tissue: strong contribution of TNF-a receptors to PAI-1 levels. Thromb Haemost 2002; 88: 481-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Panahloo A, Mohamed-Ali V, Gray RP. et al. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene. Atherosclerosis 2005; 168: 297-304.
    PubMedGoogle Scholar
  • 9 Hoekstra T, Geleijnse JM, Schouten EG. et al. Plasminogen activator inhibitor-type I: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-72.
    Article in Thieme ConnectPubMedGoogle Scholar